Artelo Biosciences Inc

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded by James Manley on May 2, 2011 and is headquartered in Solana Beach, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Expanding the patent estate for the lead clinical program to treat cancer anorexia Expanding the patent estate for the lead clinical program to treat cancer anorexia

Artelo Biosciences Files Patent Application for New Formulation of ART27.13

LA JOLLA, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15th at 9:40 a.m. PST / 12:40 p.m. EST. Gregory D. Gorgas, Artelo's President and CEO will be presenting to a live, virtual audience.

Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th

LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company's Board of Directors, effective November 30, 2020. 

Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D.

Mitacs Accelerate grant expected to fund 50% of research costs evaluating ART26.12 as a potential treatment for anxiety disorders Mitacs Accelerate grant expected to fund 50% of research costs evaluating ART26.12 as a potential treatment for anxiety disorders

Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs

First patients on track for enrollment this year

Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss

LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported financial and operating results for the fourth quarter and fiscal year ended August 31, 2020 and provided a business update.

Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update

Reports positive preclinical data in animal models Reports positive preclinical data in animal models

Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders

LA JOLLA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, today announced the closing of an underwritten public offering of units for gross proceeds of approximately $7.6 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Artelo Biosciences, Inc. The offering is comprised of units, priced at a public offering price of $0.75 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $0.75 per share that expires on the fifth anniversary of the date of issuance. The securities comprising the units are immediately separable and were issued separately.

Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option

LA JOLLA, Calif., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $6.6 million prior to deducting underwriting discounts and commissions and offering expenses payable by Artelo Biosciences, Inc.

Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering

Barry J. A. Laird, M.D. of the University of Edinburgh’s Institute of Genetics and Molecular Medicine Appointed Coordinating Investigator Barry J. A. Laird, M.D. of the University of Edinburgh’s Institute of Genetics and Molecular Medicine Appointed Coordinating Investigator

Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia

LA JOLLA, Calif., Sept.  11, 2020  (GLOBE NEWSWIRE) --   Artelo Biosciences, Inc.  (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.

Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th   

LA JOLLA, Calif., Sept.  10, 2020  (GLOBE NEWSWIRE) --   Artelo Biosciences, Inc.  (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer and Andy Yates, PhD, Interim Chief Scientific Officer, will participate in separate keynote panels at the  3  rd   Annual International Cannabinoid Derived Pharmaceuticals Summit , being held virtually on September 15-17, 2020.

Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit

LA JOLLA, Calif., July  14, 2020  (GLOBE NEWSWIRE) --  Artelo Biosciences, Inc.  (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system and related biological signaling pathways, today reported financial and operating results for the third quarter ended May 31, 2020 of its fiscal year ending August 31, 2020 and provided a business update.

Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update

Claims to Improve Drug-Like Properties of CBD Receive Intellectual Property Protection Through 2038 Claims to Improve Drug-Like Properties of CBD Receive Intellectual Property Protection Through 2038

Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal

FABP5 platform under exclusive license to Artelo Biosciences

Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program

News for Artelo Biosciences Inc Stock (ARTL)